Perampanel , a selective , noncompetitive - amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ( AMPA ) glutamate receptor antagonist , is indicated for adjunctive treatment of partial seizures in patients 12years based on three phase III clinical studies .